Cell therapy (CAR-T) · Kills target cells, directed at CS1 (SLAMF7) (SLAMF7) · developed by Cellectis
UCARTCS1A is an allogeneic, off-the-shelf T-lymphocyte cell therapy engineered with TALEN gene editing to express a chimeric antigen receptor targeting CS1 (SLAMF7), a receptor highly expressed on certain malignant plasma cells. The CAR-expressing cells bind CS1-expressing tumor cells and lyse them. It is studied in relapsed or refractory multiple myeloma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04142619 | Phase 1 | Relapsed/Refractory Multiple Myeloma | Terminated | CLLS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Relapsed/Refractory Multiple Myeloma
Updated Oct 11, 2026. Something wrong or missing? Report it on the CLLS page.
See CLLS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CLLS catalysts and pipeline →